Promotheus Laboratories launches ProOnc cancer diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Firm debuts Oct. 15 three new cancer diagnostics based on microRNA technology. ProOnc TumorSource is designed to identify tissue of origin in metastatic tumors; among the 25 tissue types it can identify are cancers of the colon, liver, brain, breast, kidney, lung, ovary, pancreas, prostate and testis, Promotheus says. ProOnc Squamous measures the expression level of a squamous microRNA biomarker to differentiate patients with and without lung cancer. ProOnc Mesothelioma differentiates malignant pleural mesothelioma from peripheral adenocarcinoma of the lung and metastatic carcinomas involving the lung and pleura, the firm says. The home brews are run at a CLIA-certified lab, the company notes